European Regulation of Consumer Product Safety

European Regulation of Consumer Product Safety

Volumn , Issue , 2012, Pages 1-336

  Hodges, Christopher ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CMS Cameron McKenna ^*  (United Kingdom)

Author keywords

Consumer products; Consumer safety; Enforcement mechanisms; European community legislation; General product safety directive; Information provision; Manufacturing environment; New approach directives; Post marketing obligations; Pre marketing assessment; Regulatory mechanisms; Safety data; Surveillance mechanisms

Indexed keywords

EID: 84920797918     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780199282555.001.0001     Document Type: Book

References (234)

1. ANON, 'French call for EC medical devices agency', Clinica 63 (1997), 10.
2. ANON, 'Medicines advice must be reliable', Doctor, 15 April 1999.
3. ANON, 'Plastic Wrapping Contaminates Food', Liability, Risk and Insurance 134 (2001).
4. ANON, 'Baxter Reports FDA Subpoena, Revises Expectations', Clinica 1050 (21 March 2003), 11.
5. ANON, 'Cancer link to fried food fails to check British appetite for chips', Sunday Telegraph, May 2002.
6. ABRAHAM, J., Science, Politics and the Pharmaceutical Industry: Controversy and Bias in Drug Regulation (London, 1995).
7. ABRAHAM, J., and LEWIS, G., Regulating Medicines in Europe (London, 2000).
8. ADAMS, J., Risk (London, 1995).
9. ANDENAS, M., and TUERK, A., (eds.), Delegated Legislation and the Role of Committees in EC (Kluwer, 2000).
10. ARMSTRONG, K., and BUTLER, S., The Governance of the Single European Market (Manchester, 1998).
11. ARMSTRONG, K., DINAN, B., and JICK, H., 'Fatal Drug Reactions in Patients Admitted to Surgical Services', Am. J Surg. 132 (1976), 643.
12. ASCH, P., Consumer Safety Regulation (Oxford, 1988).
13. ATCHIA, H., 'EN 1441-A Standard in Need of Urgent Re-think?', The Regulatory Affairs Journal (Devices) (August 1998), 181.
14. AYRES, I., and BRAITHWAITE, J., Response Regulation (Oxford, 1992).
15. AYRES, I., and BRAITHWAITE, J., Responsive Regulation-Transcending the Deregulation Debate (Oxford, 1992), 35.
16. BAIRD, D. G., GERTNER, R. H., and PICKER, R. C., Game Theory and the Law (Cambridge, Mass., 1994).
17. BAKER, D., 'Operation Frontline Felixstowe', Trading Standards Review (October 2000).
18. BALDWIN, R., Rules and Government (Oxford, 1995).
19. BALDWIN, R., and CAVE, M., Understanding Regulation (Oxford, 1999).
20. BALDWIN, R., SCOTT, C., and HOOD, C., A Reader on Regulation (Oxford, 1998).
21. BALEN, P., 'Breast Implants', Clinical Risk 8 (2002), 177-84.
22. BALL, D. J., et al., The Optimisation of Consumer Safety (London, 1998).
23. BANNISTER, J., How to Manage Risk (London, 2nd edn., 1997).
24. BARDACH, E., and KAGAN, R. A., Going by the Book: The Problem of Regulatory Unreasonableness (Philadelphia, 1982), 249-56.
25. BAXTER, A., 'Driving down the fast track', Financial Times, 30 November 1998.
26. BECK, U., Risk Society: Towards a New Modernity (London, 1992).
27. BECK, U., 'The Politics of Risk Society', in J. Franklin (ed.), The Politics of Risk Society (Cambridge, 1998).
28. BERNSTEIN, M., Regulating Business by Independent Commission (Princeton, NJ, 1955).
29. BLACK, J., Rules and Regulators (Oxford, 1997).
30. BLACK, J., 'Using Rules Effectively', in C. McCrudden (ed.), Regulation and Deregulation (Oxford, 1999).
31. BMA, Living with Risk: The British Medical Association Guide (London, 1987).
32. BOVENS, M., The Quest for Responsibility: Accountability and Citizenship in Complex Organisations (Cambridge, 1998).
33. BRADLEY, K. St C., 'Comitology and the Law: Through a Glass Darkly', CML Rev. 29 (1992).
34. BRAITHWAITE, J., Corporate Crime in the Pharmaceutical Industry (London, 1986).
35. BREYER, S., Regulation and its Reform (Cambridge, Mass., 1982).
36. BREYER, S., 'Regulation and Deregulation in the United States: Airlines, Telecommunications and Anti-Trust', in G. Majone (ed.), Deregulation or Reregulation? (London, 1990).
37. BREYER, S., Breaking the Vicious Circle (Cambridge, Mass., 1993).
38. BRITISH RETAIL CONSORTIUM, Product Recall Guidelines (London, 2003).
39. BRITTON, J., and MCNEILL, A., 'Why Britain Needs a Nicotine Regulation Agency', BMJ 322 (2001), 1077-8.
40. BRUNSSON, N., JACOBSSON, B., et al., A World of Standards (Oxford, 2000).
41. BÚRCA, G. DE, 'The Institutional Development of the EU: A Constitutional Analysis', in P. Craig and G. de Búrca (eds.), The Evolution of EU Law (Oxford, 1999).
42. CALMAN, K. C., AND ROYSTON, H. D., 'Risk Language and Dialects', BMJ 315 (1997), 939-42.
43. CARANASOS, G. J., MAY, F. E., STEWART, R. B., and CLUFF, L. E., 'Drug-Associated Deaths of Medical Inpatients', Arch. Intern. Med. 136 (1976), 872.
44. CARTWRIGHT, P., 'The Regulation of Product Safety', in G. Howells (ed.), The Law of Product Liability (London, 2000).
45. CENTRE DU DROIT DE LA CONSOMMATION, Study on the Practical Application of Directive 92/59/EEC (Louvain-la-Neuve, 2000).
46. CHAPMAN, C. R., AND MORRISON, D., 'Impacts on the Earth by Asteroids and Comets: Assessing the Hazard', Nature 367 (1994), 33-40.
47. CHETLEY, A., A Healthy Business? World Health and the Pharmaceutical Industry (London, 1990).
48. CHITI, E., 'The Emergence of a Community Administration: The Case of European Agencies', CML Rev. (2000), 309.
49. CMS CAMERON MCKENNA AND ANDERSEN CONSULTING, Final Report: Evaluation of the Operation of Community Procedures for the Authorisation of Medicinal Products (European Commission, 2000).
50. COLLIER, J., 'Patient-Information Leaflets and Prescriber Competence', The Lancet 352 (28 November 1998).
51. COLLINS, H., Regulating Contracts (Oxford, 1999).
52. CONSUMER SAFETY INSTITUTE AND ERASMUS UNIVERSITY, Costs of Injuries in the Netherlands (Amsterdam, 2000).
53. COUNCIL FOR SCIENCE AND SOCIETY, The Acceptability of Risks (Chichester, 1977).
54. COUNTERFEITING INTELLIGENCE BUREAU, Countering Counterfeiting: A Guide to Protecting and Enforcing Intellectual Property Rights (Paris, 1997).
55. CRAIG, P., and BÚRCA, G. DE, EU Law: Text, Cases, and Materials (Oxford, 2nd edn., 1998).
56. CRAIG, P., and BÚRCA, G. DE, (eds.), The Evolution of EU Law (Oxford, 1999).
57. CRANSTON, R., Regulating Business: Law and Consumer Agencies (London, 1979).
58. CROFT, J., and HARRIS, F., Writing Safety Instructions for Consumer Products (London, 1998).
59. CUNNINGHAM, G., DODD, T. R. P., GRANT, D. J., MCMURDO, M. E. T., and RICHARDS, R. M. E., 'Drug-Related Problems in Elderly Patients Admitted to Tayside Hospitals, Methods for Prevention and Subsequent Reassessment', Age and Ageing 26 (1997), 375-82.
60. CUVILLIER, A., 'The Role of the European Medicines Evaluation Agency in the Harmonisation of Pharmaceutical Regulation', in R. Goldberg and J. Lonbay (eds.), Pharmaceutical Medicine, Biotechnology, and European Law (Cambridge, 2000).
61. DAINTITH, T., 'Regulation by Contract: The New Prerogative' (1979) Current Legal Problems 41.
62. DEHOUSSE, R., 'Misfits: EU Law and the Transformation of European Governance', in C. Joerges and R. Dehousse (eds.), Good Governance in Europe's Integrated Market (Oxford, 2002).
63. DIMASI, J. A., 'New Drug Development in the United States from 1963 to 1999', Clin. Pharmacol. Ther. 69 (2001).
64. DIMASI, J. A., 'Risks in New Drug Development: Approval Success Rates for Investigational Drugs', Clin. Pharmacol. Ther. 69 (2001).
65. DIVER, C. S., 'The Optimal Precision of Administrative Rules' (1983) 93 Yale Law Journal, 65-109.
66. DOCKSEY, C. and WILLIAMS, K., 'The Commission and the Execution of Community Policy', in G. Edwards and D. Spence (eds.), The European Commission (Harlow, 1994).
67. DODDS-SMITH, I., 'Data Protection and Abridged Applications for Marketing Authorisation in the Pharmaceutical Industry', in R. Goldberg and J. Lonbay (eds.), Pharmaceutical Medicine, Biotechnology, and European Law (Cambridge, 2000).
68. DOUGLAS, M., and WILDAVSKY, A., Risk and Culture: An Essay on the Selection of Technological and Environmental Dangers (Berkeley, Calif., 1983).
69. EFPIA, Position Paper. Response to Product Liability Green Paper by European Federation of Pharmaceutical Industries and Associations (Brussels, 1999).
70. EGAN, M., Constructing a European Market (Oxford, 2001).
71. EMERSON, M., AUJEAN, M., CATINAT, M., GOYBET, P., and JACQUEMIN, A., The Economics of 1992, The E.C. Commissions Assessment of the Economic Effects of Completing the Internal Market (Oxford, 1988).
72. ERNST, F. R., and GRIZZLE A. J., 'Drug-Related Morbidity and Mortality: Updating the Cost-of-Illness Model', Journal of the American Pharmaceutical Association 41/2 (2001), 192-9.
73. EUCOMED, Improving International and European Healthcare Standardization to meet Global Safety, Regulatory and Market Need: Towards a Global Strategy-Proposals for Action, 21 August 2002.
74. EUROPEAN COMMISSION, A Guideline on the Readability of the Label and Package Leaflet of Medicinal Products for Human Use (Brussels, 1998).
75. EUROPEAN COMMISSION, Guide to the Implementation of Directives Based on the New Approach and the Global Approach (Brussels, 2000).
76. EUROPEAN CONSUMER SAFETY ASSOCIATION, Measuring the Burden of Injuries (Amsterdam, 1999).
77. EUROPEAN CONSUMER SAFETY ASSOCIATION, Priorities for Consumer Safety in the European Union: Agenda for Action (Amsterdam, 2001).
78. FALKE, J., 'Comitology: From Small Councils to Complex Networks', in M. Andenas and A. Tuerk (eds.), Delegated Legislation and the Role of Committees in the EC (Kluwer, 2000).
79. FAURE, M. G., 'Product Liability and Product Safety in Europe: Harmonization or Differentiation?' KYKLOS 53/4 (2000), 467-508.
80. FISCHHOFF, B., LICHTENSTEIN, S., SLOVIC, P., DERBY, S. L., and KEENEY, R. L., Acceptable Risk (Cambridge, 1981).
81. FLETCHER, A. P., 'Drug Safety Tests and Subsequent Clinical Experience', J Roy. Soc. Med. 71 (1978).
82. FLETCHER, A. P., Guidelines on a Medical Devices Vigilance System (Brussels, 2001), MEDDEY 2.12-1 rev. 4.
83. FLETCHER, A. P., and SHAW, S., 'The Safety of Medicines', in J. P. Griffin and J. O'Grady, The Textbook of Pharmaceutical Medicine (London, 4th edn., 2002).
84. FORSYTH, M., Union of States: The Theory and Practice of Confederation (Leicester, 1981).
85. FROUD, J., BODEN, R., OGUS, A., and STUBBS, P., Controlling the Regulators (London, 1998).
86. FURUSTEN, S., 'The Knowledge Base of Standards' in N. Brunsson, B. Jacobsson, et al., A World of Standards (Oxford, 2000).
87. GARDNER, P., and WATSON, L. J., 'Adverse Drug Reactions: A Pharmacist-Based Monitoring System', Clin. Pharmacol. Ther. 2 (1970).
88. GIDDENS, A., Beyond Left and Right (Cambridge, 1994).
89. GIDDENS, A., 'Risk Society: The Context of British Polities', in J. Franklin (ed.), The Politics of Risk Society (Cambridge, 1998).
90. GRIFFIN, J. P., and O'GRADY, J. (eds.), The Textbook of Pharmaceutical Medicine (London, 4th edn., 2002).
91. GRIFFIN, J. P., and SHAH, R. R., 'The Development of the Control of Human Medicines in Europe from Classical Times to the Year 2000', in J. P. Griffin and J. O'Grady (eds.), The Textbook of Pharmaceutical Medicine (London, 4th edn., 2002).
92. GRUBB, A. (ed.), Principles of Medical Law (Oxford, 2nd edn., 2004).
93. GUEN, J. LE, Reducing Risks, Protecting People (London, 1999).
94. HALL, C., 'Health chiefs sorry for rise in abortions caused by pill scare', Daily Telegraph, 8 April 1999.
95. HANCHER, L., Regulating for Competition: Government, Law, and the Pharmaceutical Industry in the United Kingdom and France (Oxford, 1990).
96. HANCHER, L., 'Pharmaceutical Policy and Regulation: Setting the Pace in the European Community', in P. Davis (ed.), Contested Ground: Public Purpose and Private Interest in the Regulation of Prescription Drugs (Oxford, 1996).
97. HANCHER, L., and MORAN, M., 'Conclusion: Organising Regulatory Space', in L. Hancher and M. Moran (eds.), Capitalism, Culture and Economic Regulation (Oxford, 1989).
98. HARGREAVES, I., LEWIS, J., and SPEERS, T., Towards a Better Map: Science, the Public and the Media (Swindon, 2003).
99. HAYWARD, G., 'Risk of Injury per Hour of Exposure to Consumer Products', Acad. Anal. and Prev. 28 (1996).
100. HAYWARD, G., 'Domestic and Personal Accidents: Prevention in the Absence of Professional Supervision', Accid. Anal, and Prev. 32 (2000).
101. HEATH, R., Crisis Management for Managers and Executives (London, 1998).
102. HERXHEIMER, A., 'Leaflets with NSAIDs Do Not Warn Users Clearly-a UK Survey', The Pharmaceutical Journal 262 (17 April 1999), 559-61.
103. HIRSHHORN, R., 'Regulating Quality in Product Markets', in D. Dewees (ed.), The Regulation of Quality (1983).
104. HODGES, C., Product Liability: European Laws and Practice (London, 1993).
105. HODGES, C., 'The Reuse of Medical Devices', Medical Law Review 8 (Summer 2000), 157-81.
106. HODGES, C., Multi-Party Actions (Oxford, 2001).
107. HODGES, C., 'A New EC Directive on the Safety of Consumer Products', Eur. Bus. Law Review (Nov./Dec. 2001).
108. HODGES, C., 'The Regulation of Medicinal Products and Medical Devices', in A. Grubb (ed.), The Principles of Medical Law (Oxford, 2nd edn., 2004).
109. HODGES, C., TYLER, M., and ABBOTT, H., Product Safety (London, 1996).
110. HOOD, C., and JONES, D., Accident and Design (London, 1997).
111. HOOD, C., ROTHSTEIN, H., and BALDWIN, R., The Government of Risk (Oxford, 2001).
112. HOWELLS, G., Consumer Product Safety (Dartmouth, 1998).
113. HUTTER, B. M., Regulation and Risk (Oxford, 2001).
114. JACK, A., CLARK, B., and GREEN, D., 'Boycott forces Hoechst to drop abortion pill', Financial Times, 9 April 1997.
115. JACOBS FRANCIS, G., ADVOCATE GENERAL, 'Foreword', in R. Goldberg and J. Lonbay (eds.), Pharmaceutical Medicine, Biotechnology, and European Law (Cambridge, 2000).
116. JOERGES, C., 'Paradoxes of Deregulatory Strategies at Community Level: The Example of Product Safety Policy', in G. Majone (ed.), Deregulation or Re-regulation? Regulatory Reform in Europe and the United States (London, 1990).
117. JOERGES, C., 'Scientific Expertise in Social Regulation and the European Court of Justice: Legal Frameworks for Denationalized Governance Structures', in C. Joerges, K.-H. Ladeur, and E. Vbs (eds.), Integrating Scientific Expertise into Regulatory Decision-Making, National Traditions and European Innovations (Baden-Baden, 1997).
118. JOERGES, C., 'The Law's Problems with Governance of the European Market', in C. Joerges and R. Dehousse (eds.), Good Governance in Europe's Integrated Market (Oxford, 2002).
119. JOERGES, C., SCHEPEL, H., and VOS, E., 'Delegation and the European Polity: The Law's Problem with the Role of Standardization Organizations in European Legislation', paper presented at the conference 'Political Economy of Standards Setting', European University Institute, Florence, 4-5 June 1998.
120. JONES-LEE, M. W., The Economics of Safety and Physical Risk (Oxford, 1989).
121. JURY, L., 'Pill scare drives abortions to record', Independent, 17 February 1999.
122. KARACS, I., 'Phoney cancer drug exposes EU shambles', Independent on Sunday, 26 August 2001.
123. KASPERSON, R. E., RENN, O., SLOVIC, P., et al., 'The Social Amplification of Risk: A Conceptual Framework', Risk Analysis 8/2 (1988), 177-87.
124. KAUFER, E., 'The Regulation of New Product Development in the Drug Industry', in G. Majone (ed.), Deregulation or Re-regulation? Regulatory Reform in Europe and the United States (London, 1990).
125. KAY, J., and VICKERS, J., 'Regulatory Reform: An Appraisal' in G. Majone, Deregulation or Re-regulation? Regulatory Reform in Europe and the United States (London, 1990).
126. KELLAWAY, G. S. M., 'Intensive Monitoring for Adverse Drug Effects in Patients Discharged from Acute Medical Wards', NZ Med. J 78 (1973), 525.
127. KELMAN, S., 'Cost-Benefit Analysis: An Ethical Critique' (1981) 33 Stan. LR 387.
128. KENNEDY, I. G., and GRUBB, A., Medical Law: Text with Materials (London, 2nd edn., 1994).
129. KENNEDY, I., and GRUBB, A. (eds.), Principles of Medical Law (Oxford, 1998).
130. KIRKPATRICK, N., and JONES, B., 'The TrilucentTM Breast Implant Experience', Clinical Risk 9 (2003), 1-9.
131. KLASMEIER, C., and CASTLE, G., 'Third-Party Review', The Regulatory Affairs Journal (Devices) (May 2000), 102.
132. KLEINKE, J. D., 'Commentary: Much Ado About a Good Thing', BMJ 325 (16 November 2002), 1168.
133. KRIMSKY, S., and GOLDING, D. (eds.), Social Theories of Risk (New York, 1992).
134. LANDO, O., and BEALE, H. (eds.), Principles of European Contract Law (Kluwer, 2000).
135. LENAERTS, K., and VERHOEVEN, A., 'Institutional Balance as a Guarantee for Democracy in EU Governance', in C. Joerges and R. Dehousse (eds.), Good Governance in Europe's Integrated Market (Oxford, 2002).
136. LOCK, S., and WELLS, F. (eds.), Fraud and Misconduct in Clinical Research (London, 2nd edn., 1996).
137. LUCAS, D., 'Warnings: Do They Really Make a Difference?' Safety and Health Practitioner 17/7 (1999), 18-19.
138. MACCARTHY, C., 'Cancer fears over food packets', Financial Times, 13 August 2001.
139. MCGEE, A., and WEATHERILL, S., 'The Evolution of the Single Market-Harmonisation or Liberalisation' [1990] MLR 536, 578.
140. MCINTOSH, D., and HOLMES, M., Personal Injury Awards in EC Countries (London, 2nd edn., 2003).
141. MCKECHNLE, S., 'Health on the Internet: A Mixed Blessing', Consumer Policy Review 9/3 (May/June 1999), 86.
142. MCKEE, L., and VERRALL, M., 'Drug Firms Threaten Legal Action', Pulse (17 April 1999).
143. MACNEIL, I., 'Power of Contract and Agreed Remedies' (1962) 47 Cornell Law Quarterly 495.
144. MACNEIL, I., 'Values in Contract: Internal and External' (1983) 78 Northwestern University Law Review 340.
145. MAGAT, W. A., and VISCUSI, W. K., Informational Approaches to Regulation (Cambridge, Mass., 1992).
146. MAJONE, G., 'The Rise of the Regulatory State in Europe', West European Politics 17/3, (1994), 77-101.
147. MAJONE, G., Regulating Europe (Routledge, 1996).
148. MARTYS, C. R., 'Adverse Reactions to Drugs in General Practice', Br. Med. J 2 (1979), 1194.
149. MAXWELL, A., 'Public Perception and Politics Drive EU Medical Device Regulation', Clinica 952 (2 April 2001), 4.
150. MAZEY, S., and RICHARDSON, J., 'Institutionalizing Promiscuity: Commission-Interest Group Relations in the European Union', in A. Stone Sweet, W Sandholtz, and N. Fligstein, The Institutionalization of Europe (Oxford, 2001).
151. MEDAWAR, C., Power and Dependence: Social Audit on the Safety of Medicines, (London, 1992).
152. MENLOWE, M. A., and MCCALL SMITH, A., The Duty to Rescue (Dartmouth, 1993).
153. MEYERS, S., 'Applications of De Minimis', in C. Whipple (ed.), De Minimis Risk (New York, 1987).
154. MICKLITZ, H. W., 'Consumer Rights', in A. Cassese, A. Clapham, and J. Weiler (eds.), Human Rights and the European Community: the Substantive Law, iii. Europea Union-The Human Rights Challenge, and Internationales Productsicherheitsrecht (Baden-Baden, 1995).
155. MINTZES, B., and HODGKIN, C., 'The Consumer Movement: From Single-Issue Campaigns to Long-Term Reform', in P. Davis (ed.), Contested Ground: Public Purpose and Private Interest in the Regulation of Prescription Drugs (Oxford, 1996).
156. MOE, T., 'Interests, Institutions and Positive Theory: The Politics of the NLRB', Studies in American Political Development 2: 236-99.
157. MOORE, T. J., Deadly Medicine: Why Tens of Thousands of Heart Patients Died in America's Worst Drug Disaster (New York, 1995).
158. MULROY, R., 'Iatrogenic Disease in General Practice: Its Incidence and Effects', Br. Med. J 2 (1973), 407.
159. NATIONAL CONSUMER COUNCIL, Pharmaceuticals: A Consumer Prescription: A discussion paper on the Structure and Regulation of the Pharmaceuticals Industry (London, 1991).
160. NATIONAL CONSUMER COUNCIL, Balancing Acts: Conflicts of Interest in the Regulation of Medicine (London, 1993).
161. NATIONAL CONSUMER COUNCIL, Soft Law in the European Union: A Discussion Paper on the Structure and Regulation of the Pharmaceuticals Industry (London, 2001).
162. 'New Leadership for the FDA', Lancet 360 (19 October 2002), 1183.
163. NOLL, R. G., and KRIER, J. E., 'Some Implications of Cognitive Psychology for Risk Regulation' (1990) 19 J Legal Stud. 747.
164. OECD, Recommendation of the Council Concerning the Establishment of Data Collection Systems Related to Injuries Involving Consumer Products, C (77) 139.
165. OECD, Data Collection Systems Related to Injuries Involving Consumer Products (Paris, 1978).
166. OECD, Severity Weighting of Data on Accidents Involving Consumer Products (Paris, 1979).
167. OECD, Recommendation of the Council Concerning the Safety of Consumer Products, C (79) 202, 1 December 1979.
168. OECD, Recall Procedures for Unsafe Products Sold to the Public (Paris, 1981).
169. O'GRADY, J., 'Drug Induced Injury', in J. O'Grady et al., Medicines, Medical Devices, and the Law (London, 1999).
170. OGUS, A. I., Regulation: Legal Form and Economic Theory (Oxford, 1994).
171. OGUS, A. I., 'Risk Management and "Rational", Social Regulation', in R. Baldwin (ed.), Law and Uncertainty: Risks and Legal Processes (London, 1997).
172. OWEN, B., and BRAEUTIGAM, R., The Regulation Game: Strategic Use of the Administrative Process (Cambridge, Mass.: 1978).
173. PALMER, A. H., Study on the Implementation of the Low Voltage Directive (Brussels, 1999).
174. PEDRONI, G., 'Drugs and Adverse Reactions: An Economic View of a Medical Problem', Social Science and Medicine 18/1 (1984), 73-182.
175. PELKMANS, J., 'The New Approach to Technical Harmonization and Standardization' [1987] 25 JCMS 249, 252-3.
176. PELTZMAN, S., 'Toward a More General Theory of Regulation', Journal of Economics and Law 19 (1976), 211-40.
177. PETTY, R. D., 'Regulating Product Safety: The Informational Role of the U.S. Federal Trade Commission', Journal of Consumer Policy 18 (1995), 387-415.
178. PIERCE, A., and DORAN, J., 'MPs alarmed by evidence of smuggling', The Times, 22 August 2001.
179. PILLING, D., 'Vaccine recalled amid BSE concern', Financial Times, 21 October 2000.
180. PINES, W. L. (ed.), When Lightning Strikes: A How-To Crisis Manual With Classic Case Studies (Washington, DC, 1994).
181. POLLACK, M. A., 'Delegation, Agency, and Agenda Setting in the European Community' International Organisation 51/1 (1997), 99-134.
182. POLLACK, M. A., The Engines of European Integration (Oxford, 2003).
183. PORTER, J., and JICK, H., 'Drug-Related Deaths Among Medical Inpatients', J Am. Med. Assoc. 237 (1977).
184. POWELL, A. H., Study on the Implementation of the Low Voltage Directive (Brussels, 1999).
185. POWER, M., The Audit Society (Oxford, 1997).
186. RATZAN, S. C. (ed.), The Mad Cow Crisis: Health and the Public Good (New York, 1998).
187. RAWLINS, M. D., 'Cutting the Cost of Drug Development?' Nature 3 (April 2004), 360.
188. REISS, A., 'Selecting Strategies of Social Control over Organisational Life', in K. Hawkins and J. Thomas (eds.), Enforcing Regulation (Boston, 1984).
189. Revision of Directive 92/59/EEC on General Product Safety: UNICE Comments, UNICE, 27 September 2000.
190. Revision of the Machinery Directive 98/37/EC, ORGALIME, 11.05.2001.
191. ROYAL COLLEGE OF PHYSICIANS, Research Involving Patients (London, 1990).
192. ROYAL SOCIETY, Risk Assessment (London, 1983).
193. ROYAL SOCIETY, Risk: Analysis, Perception, Management (London, 1992).
194. SANDHOLTZ, W., and STONE SWEET, S., European Integration and Supranational Governance (Oxford, 1998).
195. SCHAEFER, G. F., 'Linking Member State and European Administrations-The Role of Committees and Comitology', in M. Andenas and A. Tuerk (eds.), Delegated Legislation and the Role of Committees in the EC (Kluwer, 2000).
196. SCHLACKE, S., 'Centralization and Europeanization of Administrative Implementation: Product Safety Legislation', in M. Andenas and A. Tuerk (eds.), Delegated Legislation and the Role of Committees in the EC (Kluwer, 2000).
197. SCHRADER-FRECHETTE, K. S., Risk and Rationality (Berkeley, 1991).
198. SCHRADER-FRECHETTE, K. S., 'Uncertainty and the Producer Strategy: The Case for Minimising Type II Errors in Rational Risk Evaluation', in Risk and Rationality (Berkeley, 1991), ch. 9.
199. SCOTT, J., and VOS, E., 'The Juridification of Uncertainty: Observations on the Ambivalence of the Precautionary Principle within the EU and the WTO', in C. Joerges and R. Dehousse (eds.), Good Governance in Europe's Integrated Market (Oxford, 2002).
200. SEIDL, L. G., THORNTON, G. F., and CLUFF, L. E., 'Epidemiological Studies of Adverse Drug Reactions', Am. J Public Health 65 (1965), 1170.
201. SELZNICK, P., 'Self-Regulation and the Theory of Institutions' in G. Teubner, L. Farmer, and D. Murphy (eds.), Environmental Law and Ecological Responsibility: The Concept and Practice of Ecological Self-Organisation (London, 1994).
202. SEYMOUR, M., and MOORE, S., Effective Crisis Management (London, 2000).
203. SHAPIRO, S., SLONE, D., LEWIS, G. P., and JICK, H., 'Fatal Drug Reactions Among Medical Inpatients', J Am. Med. Assoc. 216 (1971).
204. SHAVELL, S., 'The Optimal Structure of Law Enforcement', Journal of Law and Economics (1993), 270-87.
205. SILCOCK, J., and PRITCHARD, C., To Heal and Harm: An Economic View of Drug Safety (London, 2003).
206. SLOT, P. J., 'A Contribution to the Constitutional Debate in the Light of the Tobacco Judgment' [2002] ELR 3.
207. STACK, F., and CRAMPTON, S., 'European Governance: CA's Response', Consumer Policy Review 12/3 (2002), 106-13.
208. STAPLETON, J., Product Liability (London, 1994).
209. STEELE, J., Risks and Legal Theory (Oxford, 2004).
210. STIGLER, G. I., 'The Theory of Economic Regulation', Bell Journal of Economics and Management Science, 2 (1971), 3-21.
211. STONE, C., Where the Law Ends: The Social Control of Corporate Behaviour (Prospect Heights, Ill., 1975).
212. STONE SWEET, A., SANDHOLTZ, W., and FLIGSTEIN, N., The Institutionalisation of Europe (Oxford, 2001).
213. SUGDEN, R., and WILLIAMS, A., The Principles of Practical Cost-Benefit Analysis (Oxford, 1978).
214. SUNSTEIN, C. R., Risk and Reason: Safety, Law, and the Environment (Cambridge, 2002).
215. TEFF, H., and MUNRO, C. R., Thalidomide: The Legal Aftermath (Westmead, 1976).
216. THOMPSON, M., ELLIS, R., and WILDAVSKY, A., Cultural Theory (Boulder, Colo., 1990).
217. TOLLER, A. E., and HOFMAN, C. H., 'Democracy and the Reform of Comitology', in M. Andenas and A. Tuerk (eds.), Delegated Legislation and the Role of Committees in the EC (Kluwer, 2000).
218. TOWSE, A. (ed.), Industrial Policy and the Pharmaceutical Industry (London, 1995).
219. 'UK warns unsafe medical devices could kill Europeans', Reuters, 21 September 2001.
220. UNITED NATIONS DEPARTMENT OF INTERNATIONAL ECONOMIC AND SOCIAL AFFAIRS, Guidelines for Consumer Protection (New York, 1986).
221. VAN DEN BERGH, R., 'The Subsidiarity Principle in European Community Law', Maastricht Journal of European and Comparative Law 1 (1994), 337-66.
222. VINCENT-JONES, P., 'Contractual Governance: Institutional and Organisational Analysis', Oxford Journal of Legal Studies 20/3 (2000), 317 at 341.
223. VISCUSI, W. K., Regulating Consumer Product Safety (Washington, DC, 1984).
224. VISCUSI, W. K., Fatal Tradeoffs: Public & Private Responsibilities for Risk (Oxford, 1992).
225. VOS, E., Instutional Frameworks of Community Health and Safety Regulation: Committees, Agencies and Private Bodies (Oxford, 1999).
226. VISCUSI, W. K., 'Reforming the European Commission: What Role to Play for European Agencies', 37 CML Rev. (2000), 1113.
227. WARING, A., Safety Management Systems (London, 1996).
228. WARING, A., and GLENDON, A. I., Managing Risk (London, 1998).
229. WEATHERILL, S., 'The Commission's Options for Developing EC Consumer Protection and Contract Law: Assessing the Constitutional Basis' [2002] EBLR 497.
230. WEILER, J. H. H., 'Epilogue: "Comitology" as Revolution-Infranationalism, Constitutionalism and Democracy', in C. Joerges and E. Vos (eds.), EU Committees: Social Regulation, Law and Politics (Oxford, 1999).
231. WHITE, T., and POMPONI, R., Gaining a Competitive Advantage by Building Safety into Your Products (New York, 2002).
232. WILSON, D., and ANDREWS, I., Campaigning: The A-Z of Public Advocacy (London, 1993).
233. WILSON, J. Q. (ed.), The Politics of Regulation (New York, 1980).
234. WORLD HEALTH ORGANISATION, Atlas of Mortality in Europe (Geneva, 1997).